



DOCKET NO.: 60283-USA/FMC-1213

PATENT

41635
JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Rolf Bjerkvig

Application No.: 09/763,682

Filing Date: April 27, 2001

For: Alginate Capsules For Use In The Treatment Of Brain Tumor

Confirmation No.: 8676

Group Art Unit: 1635

Examiner: Jon E. Angell

DATE OF DEPOSIT: September 29, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Karen Millane Whitney

TYPED NAME: Karen Millane Whitney
REGISTRATION NO.: 52,355

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:
- Certification in Accordance with § 1.97(e) is attached; or
- The fee of \$180.00 as set forth in § 1.17(p) is attached.
- In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).
- Copies of reference numbers 1-4 listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
- Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

DOCKET NO.: 60283-USA/FMC-1213 - 3 -

PATENT

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: September 29, 2004

Karen M. Whitney
Karen M. Whitney
Registration No. 52,355

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2004 WW

**Form PTO-1449 Modified**

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce
Patent and Trademark Office

Docket No. FMC-1213	Application No. 09/763,682
Applicant Rolf Bjerkvig	
Filing Date April 27, 2001	Group 1635
Confirmation No. 8676	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	1	5,166,137	11/24/92	Otterlei, et al.	514	23

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO

Examiner Initial

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	2	Skjåk-Bræk and Espevik, "Application of alginate gels in biotechnology and biomedicine," <i>Carbohydrates in Europe</i> , Vol. 14, pp. 19-25, 1996
	3	Kulseng <i>et al.</i> , "Alginate polylysine microcapsules as immune barrier: Permeability of cytokines and immunoglobulins over the capsule membrane," <i>Cell Transplantation</i> , Vol. 6, pp. 387-394, 1997
	4	Smidsrød and Draget, "Chemistry and physical properties of alginate," <i>Carbohydrates in Europe</i> , 14, 6-13, 1996

EXAMINER

DATE CONSIDERED